查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
多发性硬化症的全球市场:预测(2022年～2028年)
市场调查报告书
商品编码
1123146

多发性硬化症的全球市场:预测(2022年～2028年)

Global Multiple Sclerosis Market Research and Forecast 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

全球多发性硬化症的市场规模，在预测期间内预计以约2.5％的年复合成长率扩大。多发性硬化症的盛行率上升，政府的启发活动，保险偿付政策成为该市场的推动要素。

本报告提供全球多发性硬化症市场相关调查，市场概要，以及各类型，各诊断技术，各给药模式，各类药物，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 报告概要

第2章 市场概要与洞察

第3章 竞争情形

  • 主要企业分析
    • 概要
    • 财务分析
    • SWOT分析
  • 主要策略分析
  • COVID-19对主要加入企业的影响

第4章 市场决策要素

  • 促进因素
  • 阻碍因素
  • 机会

第5章 市场区隔

  • 全球多发性硬化症市场，各类型
    • 一次性进展型多发性硬化症
    • 进展型復发多发性硬化症
    • 復发型多发性硬化症
    • 次发性进展型多发性硬化症
  • 全球多发性硬化症市场，各诊断技术
    • MRI
    • 诱发电位实验
    • 脊髓液检验
    • 其他
  • 全球多发性硬化症市场，各给药模式
    • 注射剂
    • 口服剂
    • 静脉内疗法
  • 全球多发性硬化症市场，各类药物
    • 免疫调节剂
    • 免疫抑制剂

第6章 地区分析

  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第7章 企业简介

  • AbbVie Inc.
  • AB Science SA
  • Active Biotech
  • Acorda Therapeutics, Inc.
  • Bayer AG
  • Biogen Inc.
  • BrainStorm Cell Ltd.
  • CELGENE CORPORATION
  • Forward Pharma A/S
  • Genentech, Inc
  • GW Pharmaceuticals Plc
  • Johnson & Johnson Services Inc.
  • Merck KGaA
  • Medday Pharmaceuticals GmbH
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
Product Code: OMR2018268

Global Multiple Sclerosis Market Size, Share & Trends Analysis Report By Types (PPMS, PRMS, RRMS, SPMS) By Diagnostics Technologies (MRI, Evoked Potential Test, Spinal Fluid Test, and Others) By Mode of Administration (Injectable Agents, Oral Agents, and Intravenous Therapy) By Drug Class (Immunomodulators, and Immunosuppressant) Forecast, 2021-2027

The global multiple sclerosis market is anticipated to grow at a CAGR of around 2.5% during the forecast period. Multiple sclerosis is a potentially disabling disease of the brain and spinal cord. In MS communication problems between the brain and the rest of the body arises due to the attacking of immune systems on protective sheath (myelin) that covers nerve fibers. The exact mechanism of MS is not correctly understood, although several environmental, immunological, and genetic factors have been suggested in the pathogenesis of the disease. The rising prevalence of MS, awareness program by the government, and reimbursement policies are the driving factor of the MS market. According to the Multiple Sclerosis Trust, 2.5 million people in the world are estimated to have multiple sclerosis. Moreover, according to the study of McKenzie et al at the University of Dundee, the number of people with MS in the UK is growing by around 2.4% per year, due to people with MS living longer. The government program for multiple sclerosis specifically by the US government such as Emergency Assistant Program, Assistive Technology Program, and Computer Program by multiple sclerosis Focus Foundation for multiple sclerosis, played a vital role in the growth of the market.

Moreover, the shift in the preference towards oral drugs, the launch of new pipeline products, the rising need for better multiple sclerosis treatments, and rising government initiatives are expected to fulfill the market prospects during the forecast periods. The high cost of multiple sclerosis drugs and diagnostics technologies, harmful effects of the treatment and lack of awareness in the emerging economies are restraining the growth of the multiple sclerosis market. The robust range of upcoming pipeline drugs for the treatment is the opportunity of the market. The global multiple sclerosis market is hardly hit by the impact of COVID-19 due to the disruption in the supply chain and halt in the production of new drugs.

Segmental Outlook

The global multiple sclerosis market is segmented based on types, diagnostics technologies, mode of administration, and drug class. Based on types, the global multiple sclerosis is categorized into primary progressive multiple sclerosis, progressive relapsing multiple sclerosis, relapsing remitting multiple sclerosis, and secondary progressive multiple sclerosis. Among these, relapsing remitting multiple sclerosis held the major market share owing to the highest prevalence rate of RRMS globally. Based on diagnostic technologies, the market is segregated into MRI, evoked potential test, spinal fluid test, and others. Similarly, based on the mode of administration, the global market for multiple sclerosis is breakdown into injectable agents, oral agents, and intravenous therapy. Among these, the oral agents segment dominated the market in 2020, and it is further expected to maintain its dominance in the multiple sclerosis market during the forecast period. As oral agents such as dimethyl fumarate, teriflunomide, cladribine provide high satisfaction and faster relief, due to which their demand is high in multiple sclerosis treatment. Whereas according to drug class, the market is bifurcated into immunomodulators, and immunosuppressant.

Global Multiple Sclerosis Market Share by Drug Class, 2020 (%)

Global Multiple Sclerosis Market Share by Drug Class

The immunosuppressants Hold the Largest Share in Global Multiple Sclerosis Market

Among drug class, immunosuppressants dominated the market, and it is further projected to be the largest contributor in the global multiple sclerosis market during the forecast period. The rising prevalence of relapsing-remitting multiple sclerosis (RRMS) creating the demand for immunosuppressants. These drugs are highly recommended in the treatment of RRMS owing to their beneficial effects. The most commonly used immunosuppressive agents in MS are azathioprine, cyclophosphamide, methotrexate, and mitoxantrone. These agents are approved by the US FDA to be used in MS treatments. Further developments and approvals to immunosuppressants drugs are expected to propel the market growth globally during the forecast period.

Regional Outlook

Geographically, the global multiple sclerosis market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Asia-Pacific is expected to be the fastest growing in the global multiple sclerosis market during the forecast period. China, India, Malaysia are the major economies contributing highly towards the growth of the market owing to the development in the healthcare sector, and rising disposable income. Growing awareness about the diagnosis and treatment options for multiple sclerosis, and the presence of a huge patient population coupled with multiple sclerosis are also the prominent factors driving the market growth.

Global Multiple sclerosis Market Growth, By Region 2021-2027

Global Multiple sclerosis Market Growth, By Region

North America Holds the Largest Share in Global Multiple Sclerosis Market

Geographically, North America dominated the market by holding the largest share in the global multiple sclerosis market, and it is anticipated to grow at a significant CAGR during the forecast period. The market growth in the region is mainly attributed to the increasing prevalence of MS in the US region. According to The National Multiple Sclerosis Society estimates, in 2017, nearly 1 million adults (up to 913,925) were living with multiple sclerosis in the US, and this is further estimated to grow. The development in medical sectors, increasing R&D programs, are growing focus towards awareness of multiple sclerosis considered as driving factors for market growth. Besides, the availability of treatment and drugs for multiple sclerosis therapies due to the advancement in healthcare infrastructures, and government initiatives for multiple sclerosis treatment and awareness is also propelling the market growth. The presence of major market players in the region also affects the market growth positively.

Market Players Outlook

The key players in the multiple sclerosis market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include are AbbVie Inc., Bayer AG, Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., among Others. These market players are adopting several market strategies including product launch and approvals, merger and acquisition, partnership collaboration, business, and capacity expansion and others. For instance, in January 2018, Mylan has launched a generic Glatiramer Acetate injection used in the treatment of relapsing forms of multiple sclerosis (MS), in the US market.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global multiple sclerosis market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Multiple Sclerosis Industry
  • Recovery Scenario of Global Multiple Sclerosis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Multiple Sclerosis Market, By Types
    • 5.1.1. Primary Progressive MS
    • 5.1.2. Progressive Relapsing MS
    • 5.1.3. Relapsing Remitting MS
    • 5.1.4. Secondary Progressive MS
  • 5.2. Global Multiple Sclerosis Market, By Diagnostics Technologies
    • 5.2.1. MRI
    • 5.2.2. Evoked Potential Test
    • 5.2.3. Spinal Fluid Test
    • 5.2.4. Others
  • 5.3. Global Multiple Sclerosis Market, By Mode of Administration
    • 5.3.1. Injectable Agents
    • 5.3.2. Oral Agents
    • 5.3.3. Intravenous Therapy
  • 5.4. Global Multiple Sclerosis Market, By Drug Class
    • 5.4.1. Immunomodulators
    • 5.4.2. Immunosuppressant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East& Africa

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. AB Science SA
  • 7.3. Active Biotech
  • 7.4. Acorda Therapeutics, Inc.
  • 7.5. Bayer AG
  • 7.6. Biogen Inc.
  • 7.7. BrainStorm Cell Ltd.
  • 7.8. CELGENE CORPORATION
  • 7.9. Forward Pharma A/S
  • 7.10. Genentech, Inc
  • 7.11. GW Pharmaceuticals Plc
  • 7.12. Johnson & Johnson Services Inc.
  • 7.13. Merck KGaA
  • 7.14. Medday Pharmaceuticals GmbH
  • 7.15. Mylan N.V.
  • 7.16. Novartis AG
  • 7.17. Pfizer Inc.
  • 7.18. F. Hoffmann-La Roche Ltd.
  • 7.19. Sanofi S.A.
  • 7.20. Teva Pharmaceutical Industries Ltd.
  • 7.21. TG Therapeutics, Inc.

LIST OF TABLES

  • 1. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 2. GLOBAL PRIMARY PROGRESSIVE MS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL PROGRESSIVE RELAPSING MS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL RELAPSING REMITTING MS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL SECONDARY PROGRESSIVE MS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)
  • 6. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)
  • 7. GLOBAL MRI FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL EVOKED POTENTIAL TEST FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL SPINAL FLUID TEST FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 10. GLOBAL OTHERS DIAGNOSTIC TECHNOLOGIES FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 11. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 12. GLOBAL INJECTABLE AGENTS IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL ORAL AGENTS IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL INTRAVENOUS THERAPY IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 16. GLOBAL IMMUNOMODULATORS IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL IMMUNOSUPPRESSANT IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 23. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 25. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)

26. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION

  • 27. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 30. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES,2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 33. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 34. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES,2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL MULTIPLE SCLEROSIS MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL MULTIPLE SCLEROSIS MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL MULTIPLE SCLEROSIS MARKET, 2020-2027 (%)
  • 4. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY TYPES,2020 VS 2027 (%)
  • 5. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY DIAGNOSTICS TECHNOLOGIES,2020 VS 2027 (%)
  • 6. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY MODE OF ADMINISTRATION, 2020 VS 2027 (%)
  • 7. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY DRUG CLASS, 2020 VS 2027 (%)
  • 8. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL PRIMARY PROGRESSIVE MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL PROGRESSIVE RELAPSING MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RELAPSING REMITTING MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL SECONDARY PROGRESSIVE MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL MRI FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL EVOKED POTENTIAL TEST FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL SPINAL FLUID TEST FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL OTHERS DIAGNOSTIC TECHNOLOGIES FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL INJECTABLE AGENTS IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL ORAL AGENTS IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL INTRAVENOUS THERAPY IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL IMMUNOMODULATORS IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL IMMUNOSUPPRESSANT IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 22. US MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. CANADA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. UK MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. ITALY MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF EUROPE MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. INDIA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. REST OF ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET SIZE, 2021-2027($ MILLION)